TW201615188A - 奈必洛爾藥物應用於癌症治療 - Google Patents

奈必洛爾藥物應用於癌症治療 Download PDF

Info

Publication number
TW201615188A
TW201615188A TW104134945A TW104134945A TW201615188A TW 201615188 A TW201615188 A TW 201615188A TW 104134945 A TW104134945 A TW 104134945A TW 104134945 A TW104134945 A TW 104134945A TW 201615188 A TW201615188 A TW 201615188A
Authority
TW
Taiwan
Prior art keywords
cancer
nebivolol
cells
group
drug
Prior art date
Application number
TW104134945A
Other languages
English (en)
Inventor
陳丘泓
莊秀美
魏宗德
蕭乃文
Original Assignee
朗齊生物醫學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朗齊生物醫學股份有限公司 filed Critical 朗齊生物醫學股份有限公司
Publication of TW201615188A publication Critical patent/TW201615188A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

本發明提供奈必洛爾藥物的新臨床之應用。該奈必洛爾藥物是經過衛生署通過核准上市的心臟病藥物。本發明提供奈必洛爾藥物有效的抑制不同類型的癌細胞。

Description

奈必洛爾藥物應用於癌症治療
本發明係為奈必洛爾藥物的新適應症之應用，尤其該奈必洛爾藥物具有抑制多種癌症之用途。
奈必洛爾(Nebivolol)為一種β受體阻斷劑，與其他β受體阻斷劑一樣，奈必洛爾主治例如高血壓、心絞痛等的一系列心臟及血管問題。奈必洛爾是早已被FDA所認可的用藥，具有大量藥物機轉及人體研究成果資料。
由於臨床應用上的明顯差異，因此從來沒有人認為奈必洛爾具有抑制癌症細胞的可能性。
癌症長期高居全球死因之首，且罹患癌症人數更是逐年攀升，因此治療癌症儼然成為重要的課題。一般來說，癌症藥物治療無論是化學治療或標靶治療，目的多是讓癌細胞無法複製、分裂，來阻斷腫瘤的蔓延擴張。根據統計，平均每一萬個新藥約只有五個能夠進入第一期臨床試驗。進一步，許多癌細胞相繼產生抗藥性，使藥物的使用成效大幅降低，最終導致癌症治療失敗。由此可見藥物開發具有一定的困難程度。
因此，如何能讓癌症藥物的快速的可以被開發出來， 並且盡可能的減少臨床失敗的機率，在癌症病學上是一個非常急迫又重要的課題。
為解決上述的問題，本發明係針對奈必洛爾藥物進行新適應症的研發，而達到老藥新用的目標。
經過實驗設計結果顯示奈必洛爾藥物對正常細胞沒有或僅有微小的毒性，但至於奈必洛爾在正常細胞與腫瘤細胞之間是否具有選擇性的影響。
本發明提供一種制備抑制癌症之醫藥組合物之方法，其中該醫藥組合物包含一奈必洛爾藥物(Nebivolol)及一藥物可接受的鹽類所組成。
本發明一實施例中，其中該癌症係選自由胸腔相關癌症、腹腔相關癌症、內分泌相關癌症及消化道相關癌症所組成之群組。
本發明一實施例中，其中該癌症係選自由骨肉瘤相關癌症或皮膚癌相關癌症。
本發明一實施例中，其中該胸腔相關癌症係指肺癌。
本發明一實施例中，其中該腹腔相關癌症係選自由膀胱癌、腎臟癌及子宮頸癌所組成之群組。
本發明一實施例中，其中該內分泌相關癌症係選自由前列腺癌、乳癌及卵巢癌所組成之群組。
本發明一實施例中，其中該內分泌相關癌症係選自由胃癌、肝癌、大腸癌、胰臟癌及舌癌所組成之群組。
本發明一實施例中，其中該奈必洛爾藥物的有效劑量濃度為每日20mg/kg~500mg/kg。
第一圖顯示本發明奈必洛爾用藥應用於抑制癌細胞分析結果
第二圖顯示奈必洛爾用藥可對腫瘤體積之效果
第三圖顯示高劑量及低劑量奈必洛爾腫瘤生長之抑制效果
各種癌症細胞株建立
將不同癌症類型的細胞株進行繼代培養，癌症細胞種類包含肺癌、胃癌、肝癌、直腸癌、皮膚癌、子宮頸癌、前列腺癌、膀胱癌、乳癌、血癌、胰腺癌、卵巢癌、舌癌、骨肉瘤、腎臟癌，並且對照組亦使用腎臟(HEK293(Kidney))、纖維母細胞HFW(fibroblast)、肺部上皮細胞BEAS-2B(Lung Epithelial)的正常細胞做測試。(表一)
先將各細胞於培養液培養後，由於各細胞的屬性不同，因此針對不同種的細胞也要用相對應的培養液(表一)，計算細胞數目，回種2X106細胞數，然後加入培養該細胞株之培養液補至體積為10ml，繼續培養2-3天。之後將細胞計數，並分裝至96孔盤，其中每孔的細胞數目固定為3000顆，且體積為100ul。
IC50即半抑制濃度(或稱半抑制率)。在間接競爭ELISA標準曲線中是一個非常重要的資料，標準曲線是一個S型曲線。ICELISA中，不添加藥物的對照組的OD值定為B0，添加了藥物的實驗組的OD值為B，B/B0%就叫做結合率，在結合率為50%時所對應的藥物的濃度就叫做IC50。一般IC50的數值越小表示藥物的抑制效果越強。
細胞存活分析方法
將96孔盤中原有的培養液吸掉，每孔加入濃度10uM、體積100ul的市售藥物，放置72小時後，每孔再加入100ul已稀釋的WST-1試劑，該稀釋比例為培養液與WST-1原液的體積比為9：1，最後每個孔盤的總體積為200ul，然後將96孔盤放置於37度30~90分鐘，利用ELISA reader於OD450偵測吸光值，並計算各癌症細胞株之存活率。
奈必洛爾藥對於各種癌細胞分析結果 奈必洛爾對胸腔相關癌症細胞抑制效果之測試
本分析奈必洛爾對胸腔相關癌症細胞抑制效果之測試，主要針對兩種肺癌細胞進行測試，癌細胞株分別為A549和H1650兩個細胞株，各做4次的癌細胞抑制實驗結果，並且計算其平均值，結果表列如後。(表二)
奈必洛爾對腹腔相關癌症細胞抑制效果之測試
本分析奈必洛爾對腹腔相關癌症細胞抑制效果之測試，主要針對兩種腹腔相關癌症種類細胞進行測試，膀胱癌細胞株分別為TSGH和T24兩個細胞株(表三)，子宮頸癌細胞株分別為HeLa細胞株與C-33A細胞株(表四)，腎臟癌細胞株為786-O(表五)，各做4次的癌細胞抑制實驗結果，並且計算其平均值，結果表列如後。
奈必洛爾對內分泌相關癌症細胞抑制效果之測試
本分析奈必洛爾對腹腔相關癌症細胞抑制效果之測試，主要針對三種內分泌相關癌症種類細胞進行測試，前列腺癌細胞株分別為PC-3和LNCap兩個細胞株(表六)，乳癌細胞株分別為MCF7和MDA-MB-231兩個細胞株(表七)，卵巢癌細胞株分別為NIH-OVCAR-3細胞株和TOV-21G(表八)，各做4次的癌細胞抑制實驗結果，並且計算其平均值，結果表列如後。
奈必洛爾對消化道相關癌症細胞抑制效果之測試
分析奈必洛爾對消化道相關癌症細胞抑制效果之測 試，主要針對五種消化道相關癌症種類細胞進行測試，胃癌細胞株分別為AGS和MKN-45兩個細胞株(表九)，肝癌細胞株分別為HepG2和Hep3B兩個細胞株(表十)，大腸癌細胞株分別為HCT116-wt和LoVo細胞株(表十一)，胰臟癌細胞株分別為AsPC和BxPC細胞株(表十二)，舌癌細胞株為SAS細胞株(表十三)，各做4次的癌細胞抑制實驗結果，並且計算其平均值，結果表列如後。
奈必洛爾對其他癌症細胞抑制效果之測試
分析奈必洛爾對其他類型癌正進行測試，骨肉癌細胞 株為U2OS細胞株(表十四)，皮膚癌細胞株分別為A375和BCC兩個細胞株(表十五)，各做4次的癌細胞抑制實驗結果，並且計算其平均值，結果表列如後。
對照組實驗設計 奈必洛爾對正常細胞抑制效果之測試
分析奈必洛爾對多種正常細胞進行測試，正常腎臟細 胞株為HEK293細胞株(表十六)，正常肺部上皮細胞細胞株為BEAS-2B細胞株(表十七)，各做4次的癌細胞抑制實驗結果，並且計算其平均值，結果表列如後。
針對奈必洛爾對各種癌症細胞抑制效果彙整於表十八中，清楚看出奈必洛爾對於多項癌症有明顯的抑制效果。經過發明人實驗結果，奈必洛爾藥物對於不同的癌症細胞有明顯的抑制效果。(圖一)
動物實驗分析
本實驗使用雌性BALB/cAnN.Cg-Foxn1nu/CrlNarl小鼠為樣本(購自國家實驗動物中心)，體重為21±1g，皮下注射乳癌細胞(MCF7)後隨機分籠，測試藥物分成三組：正常對照組、低劑量(100mg/kg/day)、高劑量(200mg/kg/day)。腫瘤形成超過100mm3後，每天採取腹腔注射方式給予藥物；每週測量腫瘤大小兩次，腫瘤體積測量公式如下：(L×W2)；L代表腫瘤最長直徑；W代表腫瘤最短直徑。
表十九、奈必洛爾於動物實驗對癌症對癌症之抑制效果
依據第2圖之結果，低劑量與高劑量之奈必洛爾均對腫瘤具有良好之抑制效果，且於實驗過程中各組小鼠之重量均未出現明顯降低的現象，因此表示山喜多不論高低劑量在治療過程均能使受測小鼠具有良好的健康狀態而不死亡。
依據第3圖之結果，高低劑量之奈必洛爾可有效減緩腫瘤體積增長，並可同時減少腫瘤體積，其中以高劑量之山多喜具有較佳之效果。
上列詳細說明係針對本發明之一可行實施例之具體說明，惟該實施例並非用以限制本發明之專利範圍，凡未脫離本發明技藝精神所為之等效實施或變更，均應包含於本發明之專利範圍中。

Claims (8)

  1. 一種制備抑制癌症之醫藥組合物之方法，其中該醫藥組合物包含一奈必洛爾藥物(Nebivolol)及一藥物可接受的鹽類所組成。
  2. 如申請專利範圍第1項所述之方法，其中該癌症係選自由胸腔相關癌症、腹腔相關癌症、內分泌相關癌症及消化道相關癌症所組成之群組。
  3. 如申請專利範圍第1項所述之方法，其中該癌症係選自由骨肉瘤相關癌症或皮膚癌相關癌症。
  4. 如申請專利範圍第2項所述之方法，其中該胸腔相關癌症係指肺癌。
  5. 如申請專利範圍第2項所述之方法，其中該腹腔相關癌症係選自由膀胱癌、腎臟癌及子宮頸癌所組成之群組。
  6. 如申請專利範圍第2項所述之方法，其中該內分泌相關癌症係選自由前列腺癌、乳癌及卵巢癌所組成之群組。
  7. 如申請專利範圍第2項所述之方法，其中該消化道相關癌症係選自由胃癌、肝癌、大腸癌、胰臟癌及舌癌所組成之群組。
  8. 如申請專利範圍第1項所述之方法，其中該有效劑量濃度為每日20mg/kg~500mg/kg。
TW104134945A 2014-10-24 2015-10-23 奈必洛爾藥物應用於癌症治療 TW201615188A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24

Publications (1)

Publication Number Publication Date
TW201615188A true TW201615188A (zh) 2016-05-01

Family

ID=55760314

Family Applications (21)

Application Number Title Priority Date Filing Date
TW104134940A TW201615186A (zh) 2014-10-24 2015-10-23 脫克鈣藥物應用於癌症治療
TW104134936A TWI621434B (zh) 2014-10-24 2015-10-23 千憂解藥物應用於癌症治療
TW104134945A TW201615188A (zh) 2014-10-24 2015-10-23 奈必洛爾藥物應用於癌症治療
TW104134966A TW201615194A (zh) 2014-10-24 2015-10-23 氨苯蝶啶藥物應用於癌症治療
TW104134952A TW201615221A (zh) 2014-10-24 2015-10-23 炎症用藥臨床新應用
TW104134946A TWI663984B (zh) 2014-10-24 2015-10-23 神經疾病用藥臨床新應用
TW104134961A TW201615193A (zh) 2014-10-24 2015-10-23 帕羅西汀藥物應用於癌症治療
TW104134944A TW201615219A (zh) 2014-10-24 2015-10-23 呼吸系統疾病用藥臨床新應用
TW104134965A TW201615226A (zh) 2014-10-24 2015-10-23 代謝性疾病藥物臨床新應用
TW104134960A TW201615191A (zh) 2014-10-24 2015-10-23 氨氯地平藥物應用於癌症治療
TW104134956A TW201615196A (zh) 2014-10-24 2015-10-23 山喜多藥物應用於癌症治療
TW104134954A TW201615222A (zh) 2014-10-24 2015-10-23 免疫疾病用藥臨床新應用
TW104134942A TW201615195A (zh) 2014-10-24 2015-10-23 阿那格雷藥物應用於癌症治療
TW104134924A TW201615218A (zh) 2014-10-24 2015-10-23 心血管疾病藥物臨床新應用
TW104134959A TW201615223A (zh) 2014-10-24 2015-10-23 驅蟲藥臨床新應用
TW104134963A TW201615224A (zh) 2014-10-24 2015-10-23 消化系統疾病用藥臨床新應用
TW104134908A TWI672150B (zh) 2014-10-24 2015-10-23 抗生素藥物臨床新應用
TW104134933A TWI652060B (zh) 2014-10-24 2015-10-23 阿折地平藥物應用於癌症治療
TW104134928A TW201615197A (zh) 2014-10-24 2015-10-23 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療
TW104134950A TWI663969B (zh) 2014-10-24 2015-10-23 莫諾苯宗藥物應用於癌症治療
TW104134964A TW201615225A (zh) 2014-10-24 2015-10-23 內分泌疾病用藥臨床新應用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW104134940A TW201615186A (zh) 2014-10-24 2015-10-23 脫克鈣藥物應用於癌症治療
TW104134936A TWI621434B (zh) 2014-10-24 2015-10-23 千憂解藥物應用於癌症治療

Family Applications After (18)

Application Number Title Priority Date Filing Date
TW104134966A TW201615194A (zh) 2014-10-24 2015-10-23 氨苯蝶啶藥物應用於癌症治療
TW104134952A TW201615221A (zh) 2014-10-24 2015-10-23 炎症用藥臨床新應用
TW104134946A TWI663984B (zh) 2014-10-24 2015-10-23 神經疾病用藥臨床新應用
TW104134961A TW201615193A (zh) 2014-10-24 2015-10-23 帕羅西汀藥物應用於癌症治療
TW104134944A TW201615219A (zh) 2014-10-24 2015-10-23 呼吸系統疾病用藥臨床新應用
TW104134965A TW201615226A (zh) 2014-10-24 2015-10-23 代謝性疾病藥物臨床新應用
TW104134960A TW201615191A (zh) 2014-10-24 2015-10-23 氨氯地平藥物應用於癌症治療
TW104134956A TW201615196A (zh) 2014-10-24 2015-10-23 山喜多藥物應用於癌症治療
TW104134954A TW201615222A (zh) 2014-10-24 2015-10-23 免疫疾病用藥臨床新應用
TW104134942A TW201615195A (zh) 2014-10-24 2015-10-23 阿那格雷藥物應用於癌症治療
TW104134924A TW201615218A (zh) 2014-10-24 2015-10-23 心血管疾病藥物臨床新應用
TW104134959A TW201615223A (zh) 2014-10-24 2015-10-23 驅蟲藥臨床新應用
TW104134963A TW201615224A (zh) 2014-10-24 2015-10-23 消化系統疾病用藥臨床新應用
TW104134908A TWI672150B (zh) 2014-10-24 2015-10-23 抗生素藥物臨床新應用
TW104134933A TWI652060B (zh) 2014-10-24 2015-10-23 阿折地平藥物應用於癌症治療
TW104134928A TW201615197A (zh) 2014-10-24 2015-10-23 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療
TW104134950A TWI663969B (zh) 2014-10-24 2015-10-23 莫諾苯宗藥物應用於癌症治療
TW104134964A TW201615225A (zh) 2014-10-24 2015-10-23 內分泌疾病用藥臨床新應用

Country Status (9)

Country Link
US (7) US20170304388A1 (zh)
EP (3) EP3222278B1 (zh)
JP (1) JP6539345B2 (zh)
KR (1) KR102490334B1 (zh)
CN (3) CN107106523A (zh)
AU (2) AU2015335375B2 (zh)
ES (2) ES2973279T3 (zh)
TW (21) TW201615186A (zh)
WO (21) WO2016062283A1 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
TW201615186A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 脫克鈣藥物應用於癌症治療
AU2015370666B2 (en) 2014-12-22 2020-09-03 Arovella Therapeutics Limited Prevention and treatment of metastatic disease in thrombocytotic cancer patients
WO2017116049A1 (ko) * 2015-12-31 2017-07-06 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (zh) * 2016-06-15 2016-11-09 中南大学湘雅医院 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用
WO2018072135A1 (zh) * 2016-10-19 2018-04-26 微菌方舟生物科技股份有限公司 二氢吡啶类钙拮抗剂用于治疗癌症的用途
CN108066345A (zh) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 一种具有抗肿瘤作用的化合物
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
US20200179404A1 (en) * 2017-06-09 2020-06-11 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
WO2019008516A2 (en) * 2017-07-03 2019-01-10 Menri Group Ltd. TREATMENT OF CANCER WITH DIHYDROPYRIDINES
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
KR101933805B1 (ko) 2017-10-17 2018-12-28 성균관대학교산학협력단 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물
CN108186652A (zh) * 2017-12-28 2018-06-22 深圳大学 缝隙连接细胞间通迅抑制剂甘珀酸在制备预防和治疗肝细胞癌药物中的应用
AU2019214891B2 (en) 2018-01-30 2024-08-01 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
WO2019204764A1 (en) * 2018-04-19 2019-10-24 Washington University Compositions and methods of use thereof for treatment of proteinopathies
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
FR3090084B1 (fr) 2018-12-18 2023-10-13 Securengy Projectile pour armes à feu ou air comprimé pour emport liquide ou pulvérulent.
WO2020132253A1 (en) * 2018-12-19 2020-06-25 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
EP3949959A4 (en) * 2019-04-04 2022-05-11 Daegu-Gyeongbuk Medical Innovation Foundation PHARMACEUTICAL COMPOSITION COMPRISING TRIMEBUTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USED AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
WO2020206078A1 (en) * 2019-04-05 2020-10-08 University Of North Texas Health Science Center At Fort Worth Antidepressants for the treatment or prevention of memory loss and/or cognitive decline or dysfunction in aging
CA3136353A1 (en) * 2019-04-11 2020-10-15 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (zh) * 2019-05-31 2019-08-30 天津科技大学 一种噻吨溴类化合物的应用
CN110742890A (zh) * 2019-10-24 2020-02-04 暨南大学 洛美利嗪在制备抗结肠癌药物中的应用
CN110840887A (zh) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 三氯苯达唑在制备治疗乳腺癌的药物中的应用
CN110876800B (zh) * 2019-11-18 2023-06-27 中南大学 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN111067899B (zh) * 2020-01-08 2021-03-05 温州医科大学 一种抗疟药物磷酸伯氨喹在制备治疗白血病药物上的应用
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (zh) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途
CN111557941A (zh) * 2020-06-15 2020-08-21 浙江大学 Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用
CN111848717A (zh) * 2020-08-07 2020-10-30 四川大学 靶向调控线粒体能量代谢的化合物及其应用和药物
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途
CN112274525B (zh) * 2020-12-04 2022-04-08 遵义医科大学 一种化疗药物组合物及其应用
CN112336725A (zh) * 2020-12-11 2021-02-09 吴照球 甲氧苄啶的医药新用途
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN112569215A (zh) * 2020-12-30 2021-03-30 东莞市人民医院 度米芬在制备防治结直肠癌的药物中的应用
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (zh) * 2021-06-28 2022-12-30 四川大学 Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023035200A1 (zh) * 2021-09-09 2023-03-16 中国福利会国际和平妇幼保健院 五氟利多在制备治疗子宫内膜癌的药物中的应用
CN115887455B (zh) * 2022-08-04 2024-04-05 北京大学人民医院 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用
CN115778957B (zh) * 2022-11-04 2024-06-21 天津中医药大学 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用
CN118059099B (zh) * 2024-04-19 2024-06-14 四川大学华西医院 帕罗西汀联合asct2抑制剂用于制备治疗肝癌的药物中的应用及药物组合物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2150942C1 (ru) * 1993-10-01 2000-06-20 Синтекс (Ю.ЭС.ЭЙ.) Инк. Оральные суспензии, содержащие высокие дозы мофетила микофенолята
CZ287513B6 (en) * 1994-12-28 2000-12-13 Janssen Pharmaceutica Nv Nebivolol functioning as anti-atherogenic agent
CA2344057C (en) * 1998-09-15 2008-11-18 Eli Lilly And Company Treatment of persistent pain
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
CN100473644C (zh) * 2000-07-07 2009-04-01 塔夫茨大学信托人 9-取代的二甲胺四环素化合物
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
BRPI0414568A (pt) * 2003-09-18 2006-11-07 Combinatorx Inc combinações de drogas para o tratamento de neoplasmas
OA13284A (en) * 2003-11-06 2007-01-31 Corporation Celgene Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
JP2007537246A (ja) * 2004-05-12 2007-12-20 バイオランクス カンパニー リミテッド ニコチン酸誘導体を有効成分として含む癌予防及び治療剤
AU2005244988C1 (en) * 2004-05-21 2012-06-28 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
CN1279980C (zh) * 2004-10-14 2006-10-18 孔庆忠 一种抗实体肿瘤药物组合物
JP2006298781A (ja) * 2005-04-15 2006-11-02 Geno Membrane:Kk エストロン３硫酸トランスポーター活性阻害剤
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (zh) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 制备缬沙坦的方法
SI1909778T1 (en) * 2005-07-28 2018-07-31 Academisch Ziekenhuis bij de Universiteit van Amsetrdam MONOFENOLNE, BENZENDIOLE OR SULFHYDRYAL COMPOUNDS FOR THE USE IN THE TREATMENT OF MELANOMS
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
AU2007230724B2 (en) * 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
CN101099724A (zh) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 一种微粉化来曲唑及其组合物
CN101103976A (zh) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 一种含阿那曲唑的口服药物组合物及其制备工艺
WO2008085875A2 (en) * 2007-01-05 2008-07-17 Cornerstone Therapeutics Inc. R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
JP5358566B2 (ja) * 2007-06-21 2013-12-04 アムジエン・インコーポレーテツド シナカルセトおよびその塩を合成する方法
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN100563645C (zh) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 一种治疗实体肿瘤的蓓萨罗丁缓释植入剂
US20090270397A1 (en) * 2008-04-08 2009-10-29 Orlow Seth J Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (zh) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 氨氯地平在制备治疗细胞增生性疾病药物中的用途
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN101991553B (zh) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 一种依西美坦片及其制备方法
CN101863806B (zh) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 抗前列腺癌药物(r)-比卡鲁胺的制备方法
US9012511B2 (en) * 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
WO2012015023A1 (ja) * 2010-07-29 2012-02-02 国立大学法人京都大学 抗がん剤のスクリーニング方法
WO2012079232A1 (zh) * 2010-12-15 2012-06-21 Lai Hung-Cheng 用于治疗癌症的化合物及其应用
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
CN102688493B (zh) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
CN102813643B (zh) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 bumetanide在抑制肝癌细胞转移中的应用
US9757424B2 (en) * 2011-09-27 2017-09-12 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
EP2776129B2 (en) * 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
CN102600077B (zh) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 吉西他滨或其盐纳米乳剂注射液及其制备方法
ES2384069B1 (es) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet y tumores neuroblásticos
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014036654A1 (en) * 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
PT2897620T (pt) * 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
BR112015007144A2 (pt) * 2012-10-04 2017-12-12 Ab Science uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
CN102872066B (zh) * 2012-10-19 2014-07-02 厦门大学 伊维菌素及其衍生物的用途
CA3159085A1 (en) * 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (zh) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 阿那格雷及其衍生物的抗肿瘤用途
CN103396419A (zh) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 肿瘤光动力治疗药二氢卟吩e6-15-乙酯及其制备方法
CN103536925B (zh) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN103622975B (zh) * 2013-11-07 2016-06-15 广东药学院 格列吡嗪在制备治疗肿瘤药物中的应用
CN106572988B (zh) * 2014-04-08 2022-04-08 卫理公会医院 Inos抑制性组合物及其作为乳腺癌治疗剂的用途
TW201615186A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 脫克鈣藥物應用於癌症治療

Also Published As

Publication number Publication date
WO2016062265A1 (zh) 2016-04-28
KR102490334B1 (ko) 2023-01-18
TW201615221A (zh) 2016-05-01
TW201615194A (zh) 2016-05-01
WO2016062291A1 (zh) 2016-04-28
TW201615217A (zh) 2016-05-01
ES2954860T3 (es) 2023-11-27
EP3210604C0 (en) 2024-02-14
TW201615192A (zh) 2016-05-01
EP3210604B1 (en) 2024-02-14
TW201615223A (zh) 2016-05-01
TWI652060B (zh) 2019-03-01
TW201615197A (zh) 2016-05-01
US10098852B2 (en) 2018-10-16
CN107106523A (zh) 2017-08-29
JP6539345B2 (ja) 2019-07-03
US20170304387A1 (en) 2017-10-26
WO2016062272A1 (zh) 2016-04-28
US20170304286A1 (en) 2017-10-26
TW201615186A (zh) 2016-05-01
TW201615219A (zh) 2016-05-01
WO2016062269A1 (zh) 2016-04-28
TWI672150B (zh) 2019-09-21
TW201615191A (zh) 2016-05-01
EP3222278C0 (en) 2023-06-14
WO2016062278A1 (zh) 2016-04-28
KR20170084034A (ko) 2017-07-19
WO2016062285A1 (zh) 2016-04-28
TW201615226A (zh) 2016-05-01
WO2016062267A1 (zh) 2016-04-28
TW201615224A (zh) 2016-05-01
AU2015335391A1 (en) 2017-06-01
EP3235497A4 (en) 2018-06-13
EP3222278A4 (en) 2018-06-20
WO2016062266A1 (zh) 2016-04-28
US20170312260A1 (en) 2017-11-02
US20170216247A1 (en) 2017-08-03
TW201615189A (zh) 2016-05-01
WO2016062275A1 (zh) 2016-04-28
WO2016062279A1 (zh) 2016-04-28
WO2016062274A1 (zh) 2016-04-28
WO2016062277A1 (zh) 2016-04-28
TW201615184A (zh) 2016-05-01
WO2016062287A1 (zh) 2016-04-28
EP3222278B1 (en) 2023-06-14
AU2015335375A1 (en) 2017-05-18
AU2015335375B2 (en) 2020-09-10
EP3222278A1 (en) 2017-09-27
TW201615193A (zh) 2016-05-01
US20170304218A1 (en) 2017-10-26
TW201615195A (zh) 2016-05-01
ES2973279T3 (es) 2024-06-19
WO2016062281A1 (zh) 2016-04-28
US20170304388A1 (en) 2017-10-26
US10105357B2 (en) 2018-10-23
US20170304228A1 (en) 2017-10-26
CN106999470A (zh) 2017-08-01
TW201615222A (zh) 2016-05-01
EP3210604A4 (en) 2018-06-27
AU2015335391B2 (en) 2018-06-21
TW201615220A (zh) 2016-05-01
WO2016062288A1 (zh) 2016-04-28
TWI663969B (zh) 2019-07-01
WO2016062289A1 (zh) 2016-04-28
TW201615196A (zh) 2016-05-01
WO2016062271A1 (zh) 2016-04-28
TWI663984B (zh) 2019-07-01
US10045962B2 (en) 2018-08-14
CN107106550A (zh) 2017-08-29
EP3235497A1 (en) 2017-10-25
WO2016062270A1 (zh) 2016-04-28
TW201615225A (zh) 2016-05-01
JP2017532351A (ja) 2017-11-02
TWI621434B (zh) 2018-04-21
WO2016062286A1 (zh) 2016-04-28
TW201615218A (zh) 2016-05-01
EP3210604A1 (en) 2017-08-30
WO2016062290A1 (zh) 2016-04-28
WO2016062283A1 (zh) 2016-04-28

Similar Documents

Publication Publication Date Title
TW201615188A (zh) 奈必洛爾藥物應用於癌症治療
WO2022028615A1 (zh) 治疗肿瘤的方法
CA3135916A1 (en) Combined use of a-nor-5a androstane compound drug and anticancer drug
CN111228272B (zh) 药物混合物及在制备逆转肝癌索拉非尼耐药性药物中应用